Pfizer’s twice-daily danuglipron formulation to be discontinued after high rates of GI complaints
Topline data from Pfizer’s Phase 2b clinical trial investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate,...
top of page
Browse by category
Search
GLP-1-RA: Pfizer to continue danuglipron but discontinue lotiglipron
Pfizer will continue to progress its first full agonist oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate - danuglipron...
Browse by tag
bottom of page